Corticosteroids and diabetes mellitus;Corticothérapie et diabète

Presse Medicale

Volumn 41, Issue 4, 2012, Pages 393-399

  Gagliardi, Laura ^a   Le Jeunne, Claire ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; GLUCOCORTICOID; GLUCOSE;

BLOOD GLUCOSE MONITORING; DIABETES MELLITUS; DISEASE PREDISPOSITION; EPIDEMIOLOGICAL DATA; GLUCOSE BLOOD LEVEL; LANGERHANS CELL; LONG TERM CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; SENSITIVITY ANALYSIS; SHORT SURVEY;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; BLOOD GLUCOSE; DEXAMETHASONE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE AGENTS; INSULIN; INSULIN RESISTANCE; LONG-TERM CARE;

EID: 84858750517     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2012.01.008     Document Type: Short Survey

References (43)

1. Bierry H., Malloizel L. Hypoglycémic après décapsulation. C R Soc Biol 1908, 65:232.
2. Hjelmesaeth J., Hartmann A., Kofstad J., Stenstrom J., Leivestad T., Egeland T., et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997, 64:979-983.
3. Kreze A., Mikulecky M., Moravcik M. Factors influencing the development of glucose intolerance in Cushing syndrome. Acta Med Austriaca 1995, 22:110-112.
4. Ogawa A., Johnson J.H., Ohneda M., McAllister C.T., Inman L., Alam T., et al. Roles of insulin resistance and beta-cell dysfunction in dexamethasone-induced diabetes. J Clin Invest 1992, 90:497-504.
5. Wajngot A., Giacca A., Grill V., Vranic M., Efendic S. The diabetogenic effects of glucocorticoids are more pronounced in low- than in high-insulin responders. Proc Natl Acad Sci U S A 1992, 89:6035-6039.
6. Rull J.A., Conn J.W., Floyd J.C., Fajans S.S. Levels of plasma insulin during cortisone glucose tolerance tests in " nondiabetic" relatives of diabetic patients. Implications of diminished insulin secretory reserve in subclinical diabetes. Diabetes 1970, 19:1-10.
7. Huizenga N.A., Koper J.W., De Lange P., Pols H.A., Stolk R.P., Burger H., et al. A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab 1998, 83:144-151.
8. van Rossum E.F., Koper J.W., Huizenga N.A., Uitterlinden A.G., Janssen J.A., Brinkmann A.O., et al. A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. Diabetes 2002, 51:3128-3134.
9. Whorwood C.B., Donovan S.J., Flanagan D., Phillips D.I., Byrne C.D. Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes 2002, 51:1066-1075.
10. Gross K.L., Lu N.Z., Cidlowski J.A. Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol Cell Endocrinol 2009, 300:7-16.
11. Rizza R.A., Mandarino L.J., Gerich J.E. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. J Clin Endocrinol Metab 1982, 54:131-138.
12. Nosadini R., Del Prato S., Tiengo A., Valerio A., Muggeo M., Opocher G., et al. Insulin resistance in Cushing's syndrome. J Clin Endocrinol Metab 1983, 57:529-536.
13. Folli F., Saad M.J., Kahn C.R. Insulin receptor/IRS-1/PI 3-kinase signaling system in corticosteroid-induced insulin resistance. Acta Diabetol 1996, 33:185-192.
14. Hartemann-Heurtier A. Diabète cortico-induit. Traité de diabétologie coordonné par André Grimaldi. Flammarion Sciences; 2009. p. 635-40.
15. Friedman J.E., Sun Y., Ishizuka T., Farrell C.J., McCormack S.E., Herron L.M., et al. Phosphoenolpyruvate carboxykinase (GTP) gene transcription and hyperglycemia are regulated by glucocorticoids in genetically obese db/db transgenic mice. J Biol Chem 1997, 272:31475-31481.
16. Hall R.K., Sladek F.M., Granner D.K. The orphan receptors COUP-TF and HNF-4 serve as accessory factors required for induction of phosphoenolpyruvate carboxykinase gene transcription by glucocorticoids. Proc Natl Acad Sci U S A 1995, 92:412-416.
17. Horner H.C., Munck A., Lienhard G.E. Dexamethasone causes translocation of glucose transporters from the plasma membrane to an intracellular site in human fibroblasts. J Biol Chem 1987, 262:17696-17702.
18. Weinstein S.P., Wilson C.M., Pritsker A., Cushman S.W. Dexamethasone inhibits insulin-stimulated recruitment of GLUT4 to the cell surface in rat skeletal muscle. Metabolism 1998, 47:3-6.
19. Tappy L., Randin D., Vollenweider P., Vollenweider L., Paquot N., Scherrer U., et al. Mechanisms of dexamethasone-induced insulin resistance in healthy humans. J Clin Endocrinol Metab 1994, 79:1063-1069.
20. Fasshauer M., Klein J., Neumann S., Eszlinger M., Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002, 290:1084-1089.
21. Qi D., Pulinilkunnil T., An D., Ghosh S., Abrahani A., Pospisilik J.A., et al. Single-dose dexamethasone induces whole-body insulin resistance and alters both cardiac fatty acid and carbohydrate metabolism. Diabetes 2004, 53:1790-1797.
22. Lambillotte C., Gilon P., Henquin J.C. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest 1997, 99:414-423.
23. Delaunay F., Khan A., Cintra A., Davani B., Ling Z.C., Andersson A., et al. Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J Clin Invest 1997, 100:2094-2098.
24. Blondeau B., Lesage J., Czernichow P., Dupouy J.P., Breant B. Glucocorticoids impair fetal beta-cell development in rats. Am J Physiol Endocrinol Metab 2001, 281:E592-E599.
25. Gesina E., Blondeau B., Milet A., Le Nin I., Duchene B., Czernichow P., et al. Glucocorticoid signalling affects pancreatic development through both direct and indirect effects. Diabetologia 2006, 49:2939-2947.
26. Phan-Hug F., Guimiot F., Lelievre V., Delezoide A.L., Czernichow P., Breant B., et al. Potential role of glucocorticoid signaling in the formation of pancreatic islets in the human fetus. Pediatr Res 2008, 64:346-351.
27. Marco J., Calle C., Hedo J.A., Villanueva M.L. Enhanced glucagon secretion by pancreatic islets from prednisolone-treated mice. Diabetologia 1976, 12:307-311.
28. Gurwitz J.H., Bohn R.L., Glynn R.J., Monane M., Mogun H., Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994, 154:97-101.
29. Blackburn D., Hux J., Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med 2002, 17:717-720.
30. Hathaway D.K., Tolley E.A., Blakely M.L., Winsett R.P., Gaber A.O. Development of an index to predict posttransplant diabetes mellitus. Clin Transplant 1993, 7:330-338.
31. Penfornis A., Kury-Paulin S. Immunosuppressive drug-induced diabetes. Diabetes Metab 2006, 32:539-546.
32. Younes M., Neffati F., Touzi M., Hassen-Zrour S., Fendri Y., Bejia I., et al. Systemic effects of epidural and intra-articular glucocorticoid injections in diabetic and non-diabetic patients. Joint Bone Spine 2007, 74:472-476.
33. Feldman-Billard S., Du Pasquier-Fediaevsky L., Heron E. Hyperglycemia after repeated periocular dexamethasone injections in patients with diabetes. Ophthalmology 2006, 113:1720-1723.
34. Feldman-Billard S., Lissak B., Benrabah R., Kassaei R., Heron E. Intravenous pulse methylprednisolone therapy in eye disease: effect on glucose tolerance. Ophthalmology 2003, 110:2369-2371.
35. Feldman-Billard S., Lissak B., Kassaei R., Benrabah R., Heron E. Short-term tolerance of pulse methylprednisolone therapy in patients with diabetes mellitus. Ophthalmology 2005, 112:511-515.
36. Greenstone M.A., Shaw A.B. Alternate day corticosteroid causes alternate day hyperglycaemia. Postgrad Med J 1987, 63:761-764.
37. Jannot-Lamotte M.F., Raccah D. Prise en charge du diabète lors d'une corticothérapie. Presse Med 2000, 29:263-266.
38. Halimi S. Stratégie thérapeutique du diabète de type 2 : nouvelles propositions. In: Grimaldi A, editor. Traité de diabétologie. Flammarion Médecine-Sciences; 2005. p. 434-9.
39. Kasayama S., Tanaka T., Hashimoto K., Koga M., Kawase I. Efficacy of glimepiride for the treatment of diabetes occurring during glucocorticoid therapy. Diabetes Care 2002, 25:2359-2360.
40. Roussel R., Travert F., Pasquet B., Wilson P.W., Smith S.C., Goto S., et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010, 170:1892-1899.
41. American Diabetes Association Self-monitoring of blood glucose (consensus statement). Diabetes Care 1997, 19(Suppl. 1):562-566.
42. Grimaldi A., Simon D., Sachon C. Réflexion sur l'éducation thérapeutique : l'expérience du diabète. Presse Med 2009, 38:1774-1779.
43. Lapostolle F., Hamdi N., Capette J.D., Avenel A., Darricau S., Desmaizieres M. éducation de l'entourage des patients diabétiques : étude EDUCATED. Presse Med 2010, 39:1096-1097.